{"url_path":"/sec/tara/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-055463-index.html","accession_number":"0001213900-26-055463","cik":"0001359931","ticker":"TARA","issuer_name":"Protara Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-055463-index.html","primary_entity_key":"0001359931","primary_entity_name":"Protara Therapeutics, Inc."},"word_count":429,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**(Mark One)**\n\n☒ **QUARTERLY REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\n**or**\n\n \n\n☐ **TRANSITION REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period from           \nto**         \n\n \n\n**Commission File Number: 001-36694**\n\n \n\n**Protara Therapeutics, Inc.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n**Delaware**   **20-4580525**\n\n**(State or other jurisdiction of\nincorporation or organization)**   **(I.R.S. Employer\nIdentification No.)**\n\n \n\n**345 Park Avenue South**\n\n**3rd Floor**\n\n**New York, NY**\n\n**(Address of principal executive offices)**\n\n \n\n**10010**\n\n**(Zip Code)**\n\n** **\n\n**(646) 844-0337**\n\n**(Registrant’s telephone number, including\narea code)**\n\n** **\n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**   **Trading Symbol(s)**   **Name of each exchange on which registered**\n\nCommon Stock, $0.001 par value per share   TARA   The Nasdaq Global Market\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes\n☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.\nSee the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐   Accelerated filer ☐  \n\nNon-accelerated filer ☒   Smaller reporting company ☒   \n\nEmerging growth company ☐        \n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs of May 8, 2026 there were 56,204,237 shares\nof the registrant’s common stock, par value $0.001 per share, outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n \n**Page** \n\n \n \n \n\n[**PART I – FINANCIAL INFORMATION**](#a_001)\n1"}